Related Experiment Videos
Hyperprolactinaemia in patients with systemic lupus erythematosus
L Moszkorzová1, Z Lacinová, J Marek
1Institute of Rheumatology, Prague, Czech Republic.
Clinical and Experimental Rheumatology
|January 2, 2003
Summary
Elevated prolactin (PRL) levels were observed in 40% of systemic lupus erythematosus (SLE) patients, significantly more than in healthy individuals. This study did not find a link between hyperprolactinemia and disease activity, organ involvement, or anti-ds-DNA antibodies in SLE.
Area of Science:
- Endocrinology
- Rheumatology
- Immunology
Background:
- Hyperprolactinemia, characterized by elevated prolactin (PRL) serum levels, is implicated in various autoimmune conditions.
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with complex pathophysiology.
- Understanding hormonal influences like PRL in SLE is crucial for disease management.
Purpose of the Study:
- To investigate the prevalence of hyperprolactinemia in patients with SLE.
- To determine the association between elevated PRL levels and disease activity, organ involvement, and anti-ds-DNA antibodies in SLE.
- To compare PRL levels in SLE patients with those in rheumatoid arthritis (RA) patients and healthy controls.
Main Methods:
- Serum PRL levels were measured in 80 SLE patients, 28 RA patients, and 27 healthy controls using radioimmunometric assays.
- Blood samples were collected at 30-minute intervals after a 30-minute rest period in the morning.
- Statistical analysis was performed to compare PRL levels across the groups and assess associations.
Main Results:
- A significantly higher prevalence of elevated PRL levels was found in SLE patients (40.0%) compared to healthy controls (14.8%, p < 0.017).
- Elevated PRL levels were also observed in RA patients (39.3%), suggesting a potential role in autoimmune diseases beyond SLE.
- No significant association was found between elevated PRL levels and anti-ds-DNA antibodies or specific organ involvement in SLE patients.
- PRL levels showed a declining trend from the first to the third sample in SLE and RA patients, unlike in controls.
Conclusions:
- The study confirms a higher incidence of elevated prolactin in SLE patients compared to healthy controls.
- The variability and lack of correlation with disease markers suggest prolactin's role in SLE requires further investigation.
- Additional research is warranted to elucidate the precise implications of hyperprolactinemia in SLE pathogenesis and clinical presentation.